M
Mark D. Erion
Researcher at Torrey Pines Institute for Molecular Studies
Publications - 44
Citations - 2192
Mark D. Erion is an academic researcher from Torrey Pines Institute for Molecular Studies. The author has contributed to research in topics: Prodrug & Free energy perturbation. The author has an hindex of 26, co-authored 44 publications receiving 2045 citations. Previous affiliations of Mark D. Erion include University of California, San Diego.
Papers
More filters
Journal ArticleDOI
Isolation of a family of organic anion transporters from human liver and kidney.
TL;DR: The results indicate the existence of a family of organic anion transporting proteins in humans distinct from the oatp-like family of transporters.
Journal ArticleDOI
Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index
Mark D. Erion,Edward Earl Cable,Bruce R. Ito,Hongjian Jiang,James M. Fujitaki,Patricia D. Finn,Bao-Hong Zhang,Jinzhao Hou,Serge H. Boyer,Paul D. van Poelje,David L. Linemeyer +10 more
TL;DR: A cytochrome P450-activated prodrug of a phosphonate-containing TR agonist that exhibits increased TR activation in the liver relative to extrahepatic tissues and an improved therapeutic index indicates that targeting TR agonists to the liver has the potential to lower both cholesterol and triglyceride levels with an acceptable safety profile.
Journal ArticleDOI
Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist
Edward Earl Cable,Patricia D. Finn,Jeffrey W. Stebbins,Jinzhao Hou,Bruce R. Ito,Paul D. van Poelje,David L. Linemeyer,Mark D. Erion +7 more
TL;DR: MB07811 represents a novel class of liver‐targeted TR agonists with beneficial low‐density lipoprotein cholesterol‐lowering properties that may provide additional therapeutic benefit to hyperlipidemic patients with concomitant NAFLD.
Journal ArticleDOI
MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes
Mark D. Erion,Paul D. van Poelje,Qun Dang,Srinivas Rao Kasibhatla,Scott C. Potter,M. Rami Reddy,K. Raja Reddy,Tao Jiang,William N. Lipscomb +8 more
TL;DR: The findings suggest that potent and specific FBPase inhibitors represent a drug class with potential to treat type 2 diabetes through inhibition of GNG.
Journal ArticleDOI
Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
Qun Dang,Yan Liu,Daniel K. Cashion,Srinivas Rao Kasibhatla,Tao Jiang,Frank Taplin,Jason D. Jacintho,Haiqing Li,Zhili Sun,Yi Fan,Jay DaRe,Feng Tian,Wenyu Li,Tony Gibson,Lemus Robert Huerta,Paul D. van Poelje,Scott C. Potter,Mark D. Erion +17 more
TL;DR: Extensive lead optimization of both the thiazole FBPase inhibitors and their prodrugs culminated in the discovery of compound 35n (MB06322) as the first oralFBPase inhibitor advancing to human clinical trials as a potential treatment for T2DM.